April 5, 2024Cancer Research

Abstract CT180: Phase I clinical trial of CD19CAR -T cells secreting PD-1-targeting IL-21 in advanced relapsed/refractory acute lymphoblastic leukemia

View Full Paper

Ask AI

Bookmark

All five non-transplant patients with relapsed acute lymphoblastic leukemia achieved complete remission, with CD8+ T cells surging to 77.8–91.2% of circulating CD3+ T cells.
Phase I trial evaluated single-dose infusions of 0.3 to 3.0 × 10^6 PD-1Ab21-secreting CD19 CAR-T cells per kilogram in ten patients with refractory acute lymphoblastic leukemia.
Therapy showed manageable toxicity with grade ≤2 cytokine release syndrome and cleared central nervous system disease, supporting modified CAR-T platforms in refractory leukemia.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase I trial demonstrates complete remissions from IL-21-secreting CD19 CAR-T cells in refractory acute lymphoblastic leukemia, indicating enhanced antitumor efficacy and manageable safety.

Cite This Study

Yu et al. (2024) studied this question.

synapsesocial.com/papers/68e70461b6db64358767ea4b https://doi.org/10.1158/1538-7445.am2024-ct180

View Full Paper

Ask AI

Bookmark

Implication

Phase I trial demonstrates complete remissions from IL-21-secreting CD19 CAR-T cells in refractory acute lymphoblastic leukemia, indicating enhanced antitumor efficacy and manageable safety.

Abstract CT180: Phase I clinical trial of CD19CAR -T cells secreting PD-1-targeting IL-21 in advanced relapsed/refractory acute lymphoblastic leukemia

Key Points

Discussion

Implication

Cite This Study

Abstract CT180: Phase I clinical trial of CD19CAR -T cells secreting PD-1-targeting IL-21 in advanced relapsed/refractory acute lymphoblastic leukemia

Key Points

Discussion

Implication

Cite This Study